Fragile X syndrome is diagnosed through a specific DNA blood test that measures the number of CGG repeats in the FMR1 gene on the X chromosome. This is the only way to confirm the diagnosis. No physical exam, behavioral checklist, or brain scan can definitively identify it. The test can be ordered by a pediatrician, geneticist, or other clinician, and results typically classify a person into one of four categories based on their repeat count.
What the DNA Test Measures
Everyone carries a short repeating segment of DNA (called CGG repeats) in the FMR1 gene. In most people, this segment repeats fewer than 40 times, and the gene works normally, producing a protein essential for brain development. Problems arise when the number of repeats grows too large.
The test places your result into one of four categories:
- Normal: fewer than 40 CGG repeats. The gene functions as expected.
- Intermediate (gray zone): roughly 41 to 54 repeats. This range doesn’t cause symptoms but may expand slightly when passed to the next generation.
- Premutation: 55 to 200 repeats. Carriers in this range don’t have Fragile X syndrome itself, but they face risks of related conditions later in life and can pass an expanded version to their children.
- Full mutation: more than 200 repeats. At this size, the gene typically shuts down entirely through a chemical process called methylation. Without the protein the gene normally makes, Fragile X syndrome results.
About 1 in 7,000 males and 1 in 11,000 females are diagnosed with the full mutation, according to CDC estimates. The premutation is far more common: between 1 in 148 and 1 in 291 women, and between 1 in 290 and 1 in 855 men, carry it.
How the Lab Runs the Test
Two laboratory techniques are typically used together because each catches things the other misses.
PCR (polymerase chain reaction) amplifies a small stretch of DNA so the lab can count CGG repeats with precision, distinguishing alleles that differ by as little as a single repeat. It works well for normal, intermediate, and premutation-sized alleles. However, PCR struggles with full mutations because the repeat region is simply too large and too chemically modified to amplify reliably. In a male patient, the absence of a PCR result is itself a red flag suggesting a full mutation is present.
Southern blot analysis takes the opposite approach. It works with larger fragments of DNA and is the preferred method for confirming full mutations and large premutations. Critically, it can also detect whether the gene has been methylated, the chemical silencing that actually causes symptoms. The combination of the two methods gives the most complete picture: PCR for precise repeat counts in smaller alleles, and Southern blot for confirming full mutations and checking methylation status.
Why Mosaicism Complicates Results
Some people don’t have a single, uniform result across all their cells. Instead, they carry a mix: some cells with a premutation and others with a full mutation, or some cells where the full mutation is methylated and others where it isn’t. This is called mosaicism, and it matters because it can influence how severe symptoms are. Males with a full mutation who also carry some premutation-sized cells, or whose full mutations are not completely methylated, tend to have milder features.
Detecting mosaicism requires careful lab work. Standard PCR may pick up the premutation population but completely miss the full mutation cells, potentially leading to an incomplete diagnosis if used alone. Southern blot can miss very small subpopulations of cells carrying deletions or unusual alleles. For this reason, clinical guidelines recommend that when a premutation is detected, the lab should carefully examine whether any cells also carry a full mutation. In complex cases, multiple techniques may be needed to fully characterize the result.
Signs That Prompt Testing
Fragile X syndrome doesn’t usually announce itself at birth. Most children are diagnosed after developmental delays become apparent, often between ages two and four. Testing is recommended for any child showing developmental delay, intellectual disability, or autism, particularly if they also have physical features associated with Fragile X (such as a long face, prominent ears, or unusually flexible joints), a family history of Fragile X syndrome, or relatives with unexplained intellectual disability.
Testing isn’t limited to children. Adults experiencing late-onset tremor and balance problems of unknown cause may be evaluated for a related condition called Fragile X-associated tremor/ataxia syndrome, which affects premutation carriers. This is especially worth considering if there’s a family history of movement disorders or of Fragile X itself.
Carrier Screening and Prenatal Diagnosis
Because premutation carriers often have no obvious symptoms, many people don’t know they carry an expanded FMR1 gene until a child is diagnosed. Carrier screening uses the same DNA blood test and can identify women (and men) whose repeat count falls in the premutation or full mutation range before they have children. Women who are premutation carriers face a real chance of passing a full mutation to their children because the repeat region tends to expand from one generation to the next, particularly when transmitted by the mother.
For pregnancies where one parent is a known carrier, prenatal testing is available through two procedures. Chorionic villus sampling (CVS) can be performed in the first trimester, while amniocentesis is done in the second trimester. Both provide fetal DNA that can be analyzed with the same PCR and Southern blot methods used after birth. One important caveat: methylation results from CVS samples must be interpreted cautiously because the tissue tested (placental cells) may not perfectly match the fetus. If CVS results are ambiguous, a follow-up amniocentesis may be recommended to clarify the finding. Knowing the fetal sex also helps with counseling, since females with a full mutation typically have milder symptoms than males because their second X chromosome can partially compensate.
Cost and Getting Tested
The DNA test for Fragile X ranges from under $100 to about $1,000, depending on the lab, the specific methods used, and whether additional analysis for mosaicism is needed. Many insurance plans, including Medicaid, cover the test when it’s ordered for a clinical reason such as developmental delay or a known family history. Out-of-pocket costs vary by plan and may be limited to a copay or deductible. If cost is a concern, it’s worth contacting the lab directly, as some offer financial assistance programs or can provide a price estimate before the test is run.
A standard blood draw is all that’s needed. Results typically take one to three weeks. Genetic counseling before and after testing can help you understand what the results mean for your child and for other family members who may also carry an expanded gene.